NCT02448004View on ClinicalTrials.gov

Study to Assess the Absorption, Metabolism and Excretion of 14C-JNJ-63623872 After a Single Dose in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 11, 2015

Primary Completion Date

June 24, 2015

Study Completion Date

June 24, 2015

Conditions
Healthy
Interventions
DRUG

JNJ-63623872

Participants will receive a single 600-mg dose of JNJ-63623872 administered as three capsules containing 14C-labeled and unlabeled JNJ-63623872.

Trial Locations (1)

Unknown

Groningen

All Listed Sponsors
lead

Janssen Cilag N.V./S.A.

INDUSTRY

NCT02448004 - Study to Assess the Absorption, Metabolism and Excretion of 14C-JNJ-63623872 After a Single Dose in Healthy Male Participants | Biotech Hunter | Biotech Hunter